NorthWest Biotherapeutics Inc (NWBO)

[abeta]

Since 2005, more than
400 GBM trials have failed,
some after promising Phase 2 studies.

Most stunning was the news that a single tumor could display more than 20,000 mutations of the original cancerous cells.

Alexander - Thank you for posting this article -
(I am quoting it above and below)


By Joan Lappin
Oct 14th 2020
Northwest Biotherapeutics is finally ready for prime time
https://www.heraldtribune.com/story/business/2020/10/14/deduced-reckoning-northwest-biotherapeutics-ready-prime-time/3656047001/

NWBO combines material from your own resected tumor with dendritic cells (withdrawn from your blood), which are then trained in the lab to recognize your tumor. Because the DCVAX-L that is ultimately returned to your body is your body’s own enhanced material it is not rejected as foreign. Therefore, there is no toxicity to this treatment.

I own it; Gramercy Capital and all of our clients own it. In recent weeks, NWBO has finally completed its Phase 3 trial. The data has been locked and sent off to the statisticians for evaluation.

Right now, NWBO is valued at less than $1 billion. If the trial is successful, and we will know quickly, this undervaluation will correct rapidly.
Immunomedics was recently acquired for $21 billion by Gilead with a less promising drug

regards